An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients

Trial Profile

An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2018

At a glance

  • Drugs Ilixadencel (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MERECA
  • Sponsors Immunicum
  • Most Recent Events

    • 03 Apr 2018 According to an Immunicum media release, the 18-month follow-up period for the last patient treated will be completed in mid-year 2019.
    • 27 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Aug 2019.
    • 27 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top